What makes the clinical-stage biotech highlighted in today’s article, one focused on developing drugs to prevent certain diseases, worth strongly considering? Its most exciting drug candidate seeks to delay the onset of Type 1 diabetes by years – and its clinical trial results demonstrate that it does just that. As such, this firm is very likely to earn regulatory approval for its drug sometime next year – and with a market opportunity estimated to be greater than $1 billion, it’s poised to be a highly lucrative product. For more, CLICK HERE.
Its Diabetes-Delaying Drug Could Be A Game-Changer For This Under-The-Radar Biotech
- by Bob Mitchell